Opdivo Fails in Clinical Lung Cancer Trial


Opdivo was not proven as an effective monotherapy in patients with non-small cell lung cancer.

Bristol-Myers Squibb recently announced that its drug Opdivo (nivolumab) did not reach its primary endpoint in the clinical trial CheckMate-026 as a monotherapy for advanced non-small cell lung cancer (NSCLC).

The phase 3 clinical trial enrolled 541 treatment-naïve patients whose tumors tested positive for PD-L1 expression. Patients included in the trial had tumors that expressed PD-L1 at ≥ 5%.

Patients either received Opdivo every 2 weeks or a chemotherapy in squamous patients, according to a press release. The primary endpoint was progression-free survival, which was not met.

Opdivo previously received FDA-approval for the treatment of metastatic melanoma, advanced renal cell carcinoma, classical Hodgkin lymphoma, and for certain patients with metastatic NSCLC with progression on or after platinum-base chemotherapy.

“Opdivo has become a foundational treatment that is transforming cancer care across multiple tumor types,” said Giovanni Caforio, MD, chief executive officer, Bristol-Myers Squibb. “While we are disappointed CheckMate -026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase 3 CheckMate -227 study exploring the potential of the combination of Opdivo plus Yervoy for PD-L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD-L1 negative patients.”

Related Videos
Diabetes patient turn knob on end of insulin pen and dial up correct insulin dose for injection. Scale window on pen syringe showing number of units dose. Medical equipment is easy to self injection - Image credit: Orawan | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Andrea Izzotti
© 2023 MJH Life Sciences

All rights reserved.